Open Access

Functional associations among G protein-coupled neurotransmitter receptors in the human brain

BMC Neuroscience201415:16

DOI: 10.1186/1471-2202-15-16

Received: 22 July 2013

Accepted: 30 December 2013

Published: 17 January 2014

Abstract

Background

The activity of neurons is controlled by groups of neurotransmitter receptors rather than by individual receptors. Experimental studies have investigated some receptor interactions, but currently little information is available about transcriptional associations among receptors at the whole-brain level.

Results

A total of 4950 correlations between 100 G protein-coupled neurotransmitter receptors were examined across 169 brain regions in the human brain using expression data published in the Allen Human Brain Atlas. A large number of highly significant correlations were found, many of which have not been investigated in hypothesis-driven studies. The highest positive and negative correlations of each receptor are reported, which can facilitate the construction of receptor sets likely to be affected by altered transcription of one receptor (such sets always exist, but their members are difficult to predict). A graph analysis isolated two large receptor communities, within each of which receptor mRNA levels were strongly cross-correlated.

Conclusions

The presented systematic analysis shows that the mRNA levels of many G protein-coupled receptors are interdependent. This finding is not unexpected, since the brain is a highly integrated complex system. However, the analysis also revealed two novel properties of global brain structure. First, receptor correlations are described by a simple statistical distribution, which suggests that receptor interactions may be guided by qualitatively similar processes. Second, receptors appear to form two large functional communities, which might be differentially affected in brain disorders.

Keywords

Human brain G protein-coupled receptor mRNA Network Communities Receptor sets

Background

A typical neuron receives thousands of synaptic contacts [1], and each postsynaptic site can express a number of neurotransmitter receptors. Since neurons integrate signals from all receptors on their surface, their activity is determined by receptor sets and not by individual receptors.

Functional receptor groups explain why a constitutive null-mutation of a neurotransmitter receptor often produces a mild phenotype, even when the receptor is known to be important in specific brain functions [210]. Such minor functional effects can be explained by compensatory mechanisms in the developing brain, which at least partially depend on receptors that detect other neurotransmitters [4, 11].

Similarly, the absence of an entire neurotransmitter may not have a major effect on brain development and function. Serotonin (5-hydroxytryptamine, 5-HT) is an extremely abundant neurotransmitter in the brain: by some estimates, the density of serotonergic varicosities in the rat cerebral cortex is around 6·106/mm3, with each cortical neuron receiving some 200 varicosities [12]. The density of serotonergic projections may exceed that of the brain capillary system [13, 14] and must carry a significant energetic cost. However, genetic mutations and pharmacological manipulations that eliminate virtually all 5-HT in the brain produce only subtle behavioral alterations, with no gross morphological or cellular changes [1518]. Abnormally low dopamine levels in the brain can be nearly asymptomatic until around 50-80% of the substantia nigra neurons are lost [19], and ablation of dopaminergic neurons in neonatal rats does not result in any significant motor dysfunctions [20, 21]. A lack of norepinephrine due to a genetic mutation in the dopamine-β-hydroxylase gene produces an unremarkable neurological phenotype in humans [22, 23]. Mammalian thalamic nuclei can function normally in the virtual absence of GABAergic interneurons, as has been shown in mice and rats [24, 25]. Experimental evidence shows that the lack of one neurotransmitter can be compensated for by changes in other neurotransmitters: for example, serotonergic processes have been shown to permanently extend into brain areas previously occupied by dopaminergic terminals [26], and serotonin and/or dopamine may compensate for the lack of norepinephrine [27, 28]. It should be noted that at least some adult neurons have the flexibility to switch from one neurotransmitter to another in response to the environment [29].

These findings suggest that biological information in the brain is coded not by individual neurotransmitters or their receptors, but by finely-tuned neurotransmitter-receptor sets. While this hypothesis does not require that the receptors be physically linked, it is supported by the unexpected abundance of heteromeric receptor complexes [30, 31]. For example, the serotonin 5-HT2A receptor can form complexes with the metabotropic glutamate mGluR2 receptor [32] and the dopamine D2 receptor [33], which may play a major role in the action of antipsychotic drugs and hallucinogens. A heterocomplex is more than the sum of its individual receptors, since heteromerization can alter receptor mobility at the neuron surface, downstream signaling, and intracellular trafficking [32, 34].

Understanding neurotransmitter receptor sets will require new analytical and theoretical approaches. Functionally complete receptor sets have to be isolated and their dynamic properties investigated in specific brain regions and in individual cells [35]. While these studies pose technical challenges, they are likely to lead to major theoretical simplifications. Some researchers have already used this approach with considerable success [3638]. As a further step toward this goal, the present study used the Allen Human Brain Atlas [39, 40] to examine mRNA expression associations among nearly all known G protein-coupled neurotransmitter receptors in the human brain.

Results

The analysis used the mRNA expression data of 100 G protein-coupled receptors (Table 1) in 169 regions of six normal human brains presently available in the Allen Brain Atlas database (Figure 1). The mRNA amounts of many receptor pairs were very strongly correlated (Figure 2). The five strongest positive and negative correlations of each receptor are given in Table 2. The distribution of all 4950 correlations had a nearly symmetric shape, with a single mode shifted toward the positive values (Figure 3A, B). This distribution failed normality tests (Figure 3A; the Kolmogorov-Smirnov test: D = 0.024, p < 0.01; the Shapiro-Wilk test: W = 0.995, p < 0.01), but was well described by the beta distribution with the same range, mean and variance (the shape parameters α = 3.51 and β = 3.32) (Figure 3B; D = 0.015, p = 0.209). The distributions of several functionally meaningful subsets were not significantly different from the complete set (in each pair, both receptors represent the same neurotransmitter (Figure 3C): D = 0.076, p = 0.169); (in each pair, the receptors represent different neurotransmitters (Figure 3D): D = 0.004, p = 1); (in each pair, both receptors have the same G protein-coupling (Figure 3E): D = 0.015, p = 0.950); (in each pair, the receptors have different G protein-couplings (Figure 3F): D = 0.007, p = 1)).
Table 1

The analyzed G protein-coupled receptors

Number

Neurotransmitter

Receptor

Gene

Coupling

Median inter-subject correlation

1

Glutamate

mGluR1

GRM1

Gq

0.91

2

Glutamate

mGluR2

GRM2

Gi

0.37

3

Glutamate

mGluR3

GRM3

Gi

0.82

4

Glutamate

mGluR4

GRM4

Gi

0.94

5

Glutamate

mGluR5

GRM5

Gq

0.92

6

Glutamate

mGluR6

GRM6

Gi

0.12

7

Glutamate

mGluR7

GRM7

Gi

0.89

8

Glutamate

mGluR8

GRM8

Gi

0.45

9

GABA

GABABR1

GABBR1

Gi

0.78

10

GABA

GABABR2

GABBR2

Gi

0.89

11

Dopamine

D1

DRD1

Gs

0.91

12

Dopamine

D2

DRD2

Gi

0.89

13

Dopamine

D3

DRD3

Gi

0.69

14

Dopamine

D4

DRD4

Gi

0.03

15

Dopamine

D5

DRD5

Gs

0.83

16

Adrenergic

α1A

ADRA1A

Gq

0.76

17

Adrenergic

α1B

ADRA1B

Gq

0.87

18

Adrenergic

α1D

ADRA1D

Gq

0.79

19

Adrenergic

α2A

ADRA2A

Gi

0.62

20

Adrenergic

α2B

ADRA2B

Gi

0.31

21

Adrenergic

α2C

ADRA2C

Gi

0.64

22

Adrenergic

β1

ADRB1

Gs

0.59

23

Adrenergic

β2

ADRB2

Gs

0.67

24

Adrenergic

β3

ADRB3

Gs/Gi

0.15

25

Serotonin

5-HT1A

HTR1A

Gi

0.86

26

Serotonin

5-HT1B

HTR1B

Gi

0.38

27

Serotonin

5-HT1D

HTR1D

Gi

0.79

28

Serotonin

5-HT1E

HTR1E

Gi

0.82

29

Serotonin

5-HT1F

HTR1F

Gi

0.90

30

Serotonin

5-HT2A

HTR2A

Gq

0.95

31

Serotonin

5-HT2B

HTR2B

Gq

0.12

32

Serotonin

5-HT2C

HTR2C

Gq

0.92

33

Serotonin

5-HT4

HTR4

Gs

0.89

34

Serotonin

5-HT5A

HTR5A

Gs

0.89

35

Serotonin

5-HT6

HTR6

Gs

0.21

36

Serotonin

5-HT7

HTR7

Gs

0.89

37

Cholinergic

M1

CHRM1

Gq

0.53

38

Cholinergic

M2

CHRM2

Gi

0.91

39

Cholinergic

M3

CHRM3

Gq

0.96

40

Cholinergic

M4

CHRM4

Gi

0.53

41

Cholinergic

M5

CHRM5

Gq

0.63

42

Histamine

H1

HRH1

Gq

0.82

43

Histamine

H2

HRH2

Gs

0.69

44

Histamine

H3

HRH3

Gi

0.66

45

Histamine

H4

HRH4

Gi

0.09

46

Bradykinin

B1

BDKRB1

Gq

0.69

47

Bradykinin

B2

BDKRB2

Gq

0.61

48

Cholecystokinin

CCK1

CCKAR

Gq

0.46

49

Cholecystokinin

CCK2

CCKBR

Gq

0.94

50

CRH

CRF1

CRHR1

Gs

0.65

51

CRH

CRF2

CRHR2

Gs

0.35

52

Galanin

Gal1

GALR1

Gi

0.74

53

Galanin

Gal2

GALR2

Gi/Gq

0.54

54

Galanin

Gal3

GALR3

Gi

0.08

55

MCH

MCH1

MCHR1

Gi

0.70

56

MCH

MCH2

MCHR2

Gq

0.93

57

MSH

MC1

MC1R

Gs

0.73

58

MSH

MC2

MC2R

Gs

0.10

59

MSH

MC3

MC3R

Gs

0.40

60

MSH

MC4

MC4R

Gs

0.49

61

MSH

MC5

MC5R

Gs

0.04

62

NPY

Y1

NPY1R

Gi

0.91

63

NPY

Y2

NPY2R

Gi

0.74

64

NPY

Y4

PPYR1

Gi

0.18

65

NPY

Y5

NPY5R

Gi

0.86

66

NPY

Y6

NPY6R

Gi

0.36

67

Neurotensin

NT1

NTSR1

Gq

0.48

68

Neurotensin

NT2

NTSR2

Gq

0.81

69

Opioid

μ

OPRM1

Gi

0.84

70

Opioid

δ

OPRD1

Gi

0.25

71

Opioid

κ

OPRK1

Gi

0.67

72

Nociceptin

ORL-1

OPRL1

Gi

0.81

73

Orexin

OX1

HCRTR1

Gq

0.82

74

Orexin

OX2

HCRTR1

Gi

0.64

75

Oxytocin

OT

OXTR

Gq

0.75

76

Somatostatin

SST1

SSTR1

Gi

0.81

77

Somatostatin

SST2

SSTR2

Gi

0.91

78

Somatostatin

SST3

SSTR3

Gi

0.28

79

Somatostatin

SST4

SSTR4

Gi

0.07

80

Somatostatin

SST5

SSTR5

Gi

0.16

81

Tachykinin

NK1

TACR1

Gq

0.55

82

Tachykinin

NK2

TACR2

Gq

0.34

83

Tachykinin

NK3

TACR3

Gq

0.81

84

TRH

TRHR

TRHR

Gq

0.79

85

VIP

VPAC1

VIPR1

Gs

0.86

86

VIP

VPAC2

VIPR2

Gs

0.77

87

Vasopressin

V1a

AVPR1A

Gq

0.34

88

Vasopressin

V1b

AVPR1B

Gq

0.04

89

Vasopressin

V2

AVPR2

Gs

0.16

90

Adenosine

A1

ADORA1

Gi

0.66

91

Adenosine

A2A

ADORA2A

Gs

0.87

92

Adenosine

A2B

ADORA2B

Gs

0.57

93

Adenosine

A3

ADORA3

Gi

0.37

94

Purine

P2Y1

P2RY1

Gq

0.72

95

Purine

P2Y2

P2RY2

Gi/Gq

0.37

96

Purine

P2Y4

P2RY4

Gi/Gq

0.00

97

Purine

P2Y6

P2RY6

Gq

0.32

98

Purine

P2Y11

P2RY11

Gq

0.34

99

Cannabinoid

CB1

CNR1

Gi

0.90

100

Cannabinoid

CB2

CNR2

Gi

0.46

The inter-subject correlations were obtained from 6 subjects (15 cross-correlations).

https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig1_HTML.jpg
Figure 1

The mRNA expression profiles of six neurotransmitter receptors. The horizontal axis represents the 169 brain regions and the vertical axis represents the mRNA amounts (averaged across the probes and subjects). Since the numerical mRNA values are normalized and relative, they are not indicated on the vertical axis (for all six genes, it ranges from −2 to 2). Note high similarity between some of the profiles (e.g., mGluR1 and CRF1, 5-HT2A and H1).

https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig2_HTML.jpg
Figure 2

The scatter plots of the six most strongly correlated receptor pairs (out of the 4950 pairs). Each point represents the mRNA amounts (averaged across the probes and subjects) of the two receptors in one of the 169 brain regions. Considerable clustering is apparent, which indicates that in most brain regions the mRNA levels of the two receptors are either low or high simultaneously, with few regions in between. All correlations are significant at p < 10-15.

Table 2

The five strongest positive and negative correlations of each receptor with other receptors, calculated using 169 brain regions

1) mGluR1

2) mGluR2

3) mGluR3

4) mGluR4

5) mGluR5

6) mGluR6

50

0.80

72

0.65

90

0.72

57

0.93

72

0.82

88

0.63

4

0.74

18

0.64

43

0.62

50

0.76

39

0.81

4

0.63

57

0.71

43

0.63

23

0.51

1

0.74

65

0.80

57

0.60

46

0.65

97

0.60

22

0.50

46

0.68

7

0.79

50

0.54

98

0.63

23

0.58

93

0.49

47

0.66

43

0.76

47

0.53

68

−0.51

69

−0.33

6

−0.22

62

−0.64

50

−0.32

42

−0.34

52

−0.53

80

−0.34

59

−0.26

39

−0.64

46

−0.39

39

−0.35

75

−0.54

46

−0.35

69

−0.27

76

−0.68

47

−0.49

32

−0.39

40

−0.55

57

−0.55

57

−0.31

30

−0.72

57

−0.57

22

−0.42

32

−0.63

4

−0.56

4

−0.32

42

−0.76

4

−0.58

23

−0.50

7) mGluR7

8) mGluR8

9) GABA1

10) GABA2

11) D1

12) D2

5

0.79

15

0.57

10

0.63

9

0.63

65

0.74

40

0.71

72

0.76

74

0.52

92

0.57

49

0.58

21

0.74

35

0.69

62

0.65

53

0.47

1

0.49

17

0.58

22

0.71

68

0.67

65

0.65

40

0.47

98

0.49

39

0.56

43

0.70

75

0.66

42

0.64

38

0.46

50

0.47

34

0.56

33

0.69

100

0.66

50

−0.40

50

−0.34

8

−0.25

54

−0.27

4

−0.31

50

−0.49

57

−0.50

4

−0.35

32

−0.25

27

−0.28

47

−0.32

77

−0.50

46

−0.50

98

−0.39

41

−0.28

12

−0.31

69

−0.32

46

−0.60

4

−0.52

1

−0.39

14

−0.31

83

−0.32

57

−0.34

85

−0.67

47

−0.59

57

−0.43

53

−0.31

32

−0.41

54

−0.35

49

−0.70

13) D3

14) D4

15) D5

16) α1A

17) α1B

18) α1D

91

0.68

51

0.40

72

0.66

84

0.52

56

0.63

72

0.76

27

0.65

70

0.22

75

0.63

63

0.38

39

0.63

36

0.72

33

0.64

98

0.18

68

0.62

7

0.31

30

0.63

5

0.71

21

0.63

97

0.17

52

0.61

94

0.26

42

0.59

2

0.64

12

0.62

46

0.17

82

0.60

79

0.26

55

0.59

39

0.64

34

−0.19

7

−0.29

1

−0.47

39

−0.14

35

−0.29

47

−0.39

10

−0.22

9

−0.31

46

−0.49

74

−0.16

57

−0.30

80

−0.43

49

−0.24

94

−0.31

50

−0.50

90

−0.18

54

−0.30

46

−0.45

46

−0.27

68

−0.34

57

−0.60

20

−0.22

64

−0.30

4

−0.53

50

−0.30

60

−0.35

4

−0.60

44

−0.31

4

−0.35

57

−0.54

19) α2A

20) α2B

21) α2C

22) β1

23) β2

24) β3

73

0.63

91

0.50

11

0.74

29

0.74

93

0.68

78

0.69

81

0.50

13

0.43

33

0.67

11

0.71

100

0.62

79

0.67

83

0.49

12

0.42

91

0.65

39

0.71

68

0.60

100

0.63

7

0.48

35

0.40

27

0.65

37

0.69

97

0.59

82

0.61

52

0.47

43

0.33

13

0.63

56

0.69

40

0.58

89

0.57

91

−0.27

80

−0.24

57

−0.25

47

−0.44

6

−0.50

77

−0.19

4

−0.27

49

−0.27

47

−0.26

54

−0.44

85

−0.53

98

−0.20

47

−0.29

25

−0.31

1

−0.29

69

−0.45

34

−0.56

56

−0.22

50

−0.30

34

−0.32

46

−0.32

57

−0.50

4

−0.57

85

−0.30

46

−0.33

77

−0.33

50

−0.34

4

−0.53

57

−0.59

49

−0.31

25) 5-HT1A

26) 5-HT1B

27) 5-HT1D

28) 5-HT1E

29) 5-HT1F

30) 5-HT2A

39

0.66

40

0.67

21

0.65

65

0.62

56

0.87

42

0.84

62

0.64

100

0.61

13

0.65

5

0.58

30

0.83

29

0.83

42

0.64

82

0.61

94

0.63

62

0.56

86

0.80

39

0.80

30

0.64

78

0.61

40

0.60

39

0.55

55

0.78

55

0.80

7

0.62

35

0.60

33

0.59

43

0.53

39

0.78

56

0.76

20

−0.31

1

−0.30

49

−0.30

14

−0.17

66

−0.35

54

−0.40

47

−0.35

98

−0.32

98

−0.32

95

−0.19

69

−0.39

1

−0.43

54

−0.35

49

−0.38

1

−0.32

57

−0.24

57

−0.46

47

−0.54

57

−0.49

85

−0.39

46

−0.44

4

−0.25

54

−0.48

57

−0.71

4

−0.51

46

−0.46

50

−0.46

54

−0.30

4

−0.49

4

−0.72

31) 5-HT2B

32) 5-HT2C

33) 5-HT4

34) 5-HT5A

35) 5-HT6

36) 5-HT7

61

0.54

75

0.70

65

0.79

85

0.63

12

0.69

18

0.72

35

0.54

68

0.64

5

0.71

49

0.63

40

0.65

72

0.72

45

0.53

94

0.63

11

0.69

77

0.59

100

0.63

38

0.65

58

0.51

12

0.61

21

0.67

1

0.56

26

0.60

7

0.60

88

0.48

40

0.60

62

0.67

10

0.56

27

0.56

68

0.59

62

−0.16

85

−0.61

46

−0.45

40

−0.44

46

−0.33

57

−0.46

17

−0.18

1

−0.63

57

−0.48

78

−0.47

77

−0.35

80

−0.47

49

−0.21

98

−0.64

50

−0.49

95

−0.47

56

−0.39

49

−0.49

85

−0.21

46

−0.70

4

−0.50

100

−0.54

85

−0.50

85

−0.61

56

−0.24

50

−0.76

47

−0.50

23

−0.56

49

−0.54

46

−0.62

37) M1

38) M2

39) M3

40) M4

41) M5

42) H1

43

0.73

36

0.65

5

0.81

12

0.71

75

0.80

30

0.84

39

0.70

72

0.63

30

0.80

100

0.70

53

0.65

39

0.80

22

0.69

15

0.59

42

0.80

68

0.69

68

0.63

62

0.77

29

0.67

26

0.57

43

0.78

75

0.68

82

0.61

55

0.74

56

0.65

53

0.53

29

0.78

26

0.67

83

0.59

5

0.73

59

−0.36

46

−0.45

69

−0.40

49

−0.53

1

−0.47

50

−0.43

44

−0.37

99

−0.45

54

−0.44

1

−0.55

46

−0.52

1

−0.45

57

−0.45

80

−0.46

47

−0.44

85

−0.58

50

−0.53

47

−0.54

4

−0.45

77

−0.50

57

−0.62

50

−0.58

49

−0.60

57

−0.72

69

−0.55

85

−0.53

4

−0.64

46

−0.64

85

−0.69

4

−0.76

43) H2

44) H3

45) H4

46) B1

47) B2

48) CCK1

39

0.78

69

0.42

58

0.56

50

0.78

46

0.76

67

0.67

5

0.76

12

0.39

89

0.54

47

0.76

4

0.66

75

0.53

72

0.73

9

0.39

35

0.53

85

0.70

57

0.63

41

0.52

37

0.73

4

0.36

31

0.53

4

0.68

50

0.61

53

0.49

11

0.70

20

0.29

61

0.52

57

0.66

6

0.53

58

0.46

80

−0.30

16

−0.31

86

−0.19

36

−0.62

62

−0.50

46

−0.26

47

−0.35

29

−0.32

98

−0.24

40

−0.64

52

−0.52

50

−0.33

69

−0.42

55

−0.33

56

−0.24

75

−0.69

30

−0.54

85

−0.34

4

−0.50

37

−0.37

85

−0.30

68

−0.69

42

−0.54

49

−0.35

57

−0.50

97

−0.38

49

−0.31

32

−0.70

7

−0.59

98

−0.38

49) CCK2

50) CRF1

51) CRF2

52) Gal1

53) Gal2

54) Gal3

85

0.93

1

0.80

14

0.40

15

0.61

75

0.75

64

0.62

56

0.78

46

0.78

85

0.39

68

0.61

73

0.67

78

0.56

77

0.71

4

0.76

86

0.34

60

0.59

41

0.65

100

0.56

98

0.67

57

0.74

49

0.31

73

0.57

83

0.64

24

0.55

46

0.63

98

0.71

22

0.30

32

0.57

82

0.63

89

0.55

41

−0.60

40

−0.58

94

−0.29

57

−0.52

50

−0.48

39

−0.44

75

−0.67

94

−0.61

36

−0.29

1

−0.53

46

−0.49

85

−0.44

100

−0.69

68

−0.66

75

−0.33

50

−0.56

49

−0.58

29

−0.48

12

−0.70

75

−0.68

41

−0.34

46

−0.56

98

−0.59

49

−0.54

66

−0.71

32

−0.76

68

−0.41

4

−0.58

85

−0.63

56

−0.63

55) MCH1

56) MCH2

57) MC1

58) MC2

59) MC3

60) MC4

30

0.80

29

0.87

4

0.93

45

0.56

60

0.34

52

0.59

29

0.78

49

0.78

50

0.74

35

0.54

69

0.29

32

0.56

42

0.74

30

0.76

1

0.71

61

0.53

44

0.27

68

0.56

39

0.72

39

0.75

46

0.66

31

0.51

41

0.26

75

0.55

56

0.71

86

0.74

47

0.63

100

0.47

84

0.24

15

0.47

47

−0.29

12

−0.43

15

−0.60

86

−0.18

2

−0.24

98

−0.38

44

−0.33

100

−0.44

39

−0.62

56

−0.21

23

−0.24

1

−0.40

69

−0.36

64

−0.46

76

−0.65

85

−0.25

90

−0.25

47

−0.44

57

−0.50

66

−0.55

30

−0.71

98

−0.25

3

−0.26

50

−0.45

4

−0.52

54

−0.63

42

−0.72

49

−0.25

37

−0.36

46

−0.54

61) MC5

62) Y1

63) Y2

64) Y4

65) Y5

66) Y6

88

0.55

65

0.93

7

0.59

54

0.62

62

0.93

100

0.66

31

0.54

42

0.77

42

0.53

100

0.59

5

0.80

75

0.63

58

0.53

5

0.73

62

0.51

96

0.57

33

0.79

12

0.61

45

0.52

39

0.70

65

0.50

89

0.57

11

0.74

82

0.58

6

0.51

33

0.67

30

0.45

24

0.55

39

0.73

36

0.57

11

−0.12

46

−0.39

46

−0.34

85

−0.33

46

−0.38

46

−0.45

90

−0.14

50

−0.43

57

−0.40

30

−0.36

50

−0.44

77

−0.51

98

−0.14

47

−0.50

50

−0.41

49

−0.39

47

−0.49

56

−0.55

91

−0.14

57

−0.57

47

−0.47

86

−0.40

57

−0.54

85

−0.70

22

−0.16

4

−0.64

4

−0.51

56

−0.46

4

−0.59

49

−0.71

67) NT1

68) NT2

69) μ

70) δ

71) κ

72) ORL-1

48

0.67

75

0.81

4

0.49

43

0.61

72

0.52

5

0.82

75

0.65

94

0.77

57

0.44

22

0.60

62

0.51

7

0.76

68

0.64

40

0.69

44

0.42

37

0.59

65

0.48

18

0.76

82

0.57

12

0.67

1

0.39

56

0.58

5

0.46

39

0.74

41

0.56

32

0.64

9

0.39

90

0.57

17

0.45

43

0.73

85

−0.40

57

−0.56

42

−0.40

66

−0.25

50

−0.13

80

−0.40

50

−0.46

4

−0.57

39

−0.40

83

−0.27

46

−0.18

47

−0.47

46

−0.48

85

−0.61

43

−0.42

53

−0.28

4

−0.18

46

−0.53

57

−0.48

50

−0.66

22

−0.45

4

−0.28

57

−0.19

57

−0.58

4

−0.49

46

−0.69

37

−0.55

69

−0.39

14

−0.19

4

−0.60

73) OX1

74) OX2

75) OT

76) SST1

77) SST2

78) SST3

83

0.69

53

0.54

68

0.81

42

0.72

99

0.77

100

0.78

53

0.67

41

0.53

41

0.80

62

0.66

49

0.71

82

0.73

75

0.64

8

0.52

53

0.75

39

0.64

85

0.70

24

0.69

19

0.63

73

0.50

82

0.72

30

0.62

34

0.59

79

0.66

41

0.57

38

0.48

32

0.70

65

0.61

80

0.57

40

0.66

1

−0.39

92

−0.35

98

−0.59

1

−0.41

12

−0.50

34

−0.47

85

−0.45

50

−0.36

49

−0.67

46

−0.43

93

−0.50

77

−0.49

46

−0.48

77

−0.39

50

−0.68

50

−0.46

66

−0.51

46

−0.49

50

−0.51

98

−0.41

46

−0.69

57

−0.65

95

−0.53

49

−0.53

98

−0.53

85

−0.43

85

−0.73

4

−0.68

100

−0.54

85

−0.59

79) SST4

80) SST5

81) NK1

82) NK2

83) NK3

84) TRHR

24

0.67

50

0.61

40

0.66

100

0.77

73

0.69

16

0.52

78

0.66

85

0.59

27

0.59

78

0.73

53

0.64

67

0.51

100

0.60

46

0.58

94

0.57

75

0.72

75

0.64

32

0.51

82

0.58

77

0.57

12

0.57

40

0.65

82

0.64

75

0.51

2

0.54

4

0.56

82

0.57

83

0.64

41

0.59

83

0.50

77

−0.17

18

−0.43

4

−0.36

4

−0.42

49

−0.54

49

−0.38

57

−0.18

23

−0.44

57

−0.36

50

−0.44

46

−0.54

50

−0.38

4

−0.20

38

−0.46

1

−0.40

49

−0.54

50

−0.55

85

−0.38

49

−0.25

75

−0.46

50

−0.46

46

−0.59

85

−0.57

98

−0.40

85

−0.29

36

−0.47

46

−0.49

85

−0.63

98

−0.58

46

−0.43

85) VPAC1

86) VPAC2

87) V1a

88) V1b

89) V2

90) A1

49

0.93

29

0.80

76

0.46

6

0.63

100

0.65

3

0.72

77

0.70

56

0.74

19

0.44

61

0.55

78

0.63

98

0.59

46

0.70

30

0.67

7

0.40

31

0.48

24

0.57

70

0.57

98

0.68

55

0.62

32

0.40

58

0.43

64

0.57

43

0.53

50

0.65

22

0.62

52

0.39

96

0.38

54

0.55

39

0.53

12

−0.67

66

−0.35

50

−0.32

30

−0.22

98

−0.34

84

−0.34

41

−0.69

4

−0.36

46

−0.33

39

−0.23

77

−0.37

53

−0.34

66

−0.70

69

−0.38

57

−0.36

62

−0.25

56

−0.39

73

−0.34

75

−0.73

64

−0.40

4

−0.36

22

−0.26

85

−0.47

32

−0.36

100

−0.74

54

−0.42

47

−0.39

23

−0.26

49

−0.50

83

−0.39

91) A2A

92) A2B

93) A3

94) P2Y1

95) P2Y2

96) P2Y4

13

0.68

9

0.57

23

0.68

68

0.77

100

0.58

64

0.57

21

0.65

99

0.51

100

0.59

32

0.63

23

0.55

24

0.52

11

0.55

22

0.46

41

0.57

27

0.63

40

0.54

79

0.47

27

0.53

56

0.45

97

0.56

21

0.58

12

0.49

89

0.44

12

0.53

49

0.44

78

0.55

81

0.57

38

0.49

54

0.43

10

−0.25

53

−0.28

99

−0.37

57

−0.45

99

−0.46

86

−0.17

55

−0.25

100

−0.31

34

−0.43

4

−0.46

34

−0.47

62

−0.18

87

−0.25

66

−0.34

49

−0.48

1

−0.48

77

−0.53

42

−0.18

19

−0.27

54

−0.34

77

−0.50

46

−0.55

49

−0.54

30

−0.19

76

−0.29

74

−0.35

85

−0.53

50

−0.61

85

−0.54

87

−0.23

97) P2Y6

98) P2Y11

99) CB1

100) CB2

    

2

0.60

50

0.71

77

0.77

78

0.78

    

23

0.59

85

0.68

49

0.54

82

0.77

    

93

0.56

49

0.67

85

0.53

40

0.70

    

15

0.49

46

0.64

92

0.51

12

0.66

    

3

0.48

1

0.63

80

0.46

66

0.66

    

1

−0.31

73

−0.53

93

−0.37

46

−0.49

    

80

−0.36

83

−0.58

23

−0.38

34

−0.54

    

44

−0.38

75

−0.59

100

−0.38

77

−0.54

    

57

−0.45

53

−0.59

38

−0.45

49

−0.69

    

4

−0.50

32

−0.64

95

−0.46

85

−0.74

    

The receptor numbers (Table 1) are given in the left column and the correlations in the right column (e.g., mGluR1 has the strongest positive correlation with CRF1 (0.80)). Correlations with an absolute value of less than 0.34 are not significant after the Bonferroni correction (at α = 0.05) and should be interpreted with caution. The actual correlations may be somewhat stronger due the imperfect reliability of the expression data (the statistical “attenuation” phenomenon).

For compactness, the following abbreviations were used: GABA1 = GABABR1, GABA2 = GABABR2.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig3_HTML.jpg
Figure 3

The statistical distributions of all correlations and their subsets. A, B, The distribution of all correlations and their approximations with the normal distribution (A) and the beta distribution (B). Both theoretical distributions have the sample mean and variance. C, The distribution of the correlations between receptors that represent the same neurotransmitter (in different pairs, the neurotransmitters may be different). D , The distribution of the correlations between receptors that represent different neurotransmitters. E , The distribution of the correlations between receptors that have the same G protein-coupling (in different pairs, the couplings may be different). F , The distribution of the correlations between receptors that have different G protein-couplings. G , The distribution of the correlations of a simulated sample of 100 sets, each of which contains 169 independent, normally distributed numbers (with mean = 0 and standard deviation = 1). The simulation shows that the distribution of the correlations between G protein-coupled receptors is different from what would be expected from a matching sample of uncorrelated sets.

All statistically significant correlations among the receptors were plotted as a graph (Figure 4A). The nociceptin receptor (ORL-1) had the highest vertex degree (connectivity), due to its significant correlations with 58 receptors (Figure 4B). The largest clique consisted of 18 completely interconnected vertices: the glutamate receptors mGluR2, mGluR4, mGluR7, the adrenergic receptors α1B, α1D, β1, the serotonin receptors 5-HT1A, 5-HT1F, 5-HT2A, the cholinergic receptors M1, M3, the histamine receptors H1, H2, the melanin-concentrating hormone MCH1, the neuropeptide Y receptors Y1, Y5, the nociceptin receptor (ORL-1), and the somatostatin receptor SST1. The distribution of the vertex degrees (the number of links originating in each receptor) appeared to be bimodal and did not follow the power law that is often observed in natural networks with high functional connectivity (Figure 4A, inset). However, a recent study has shown that a bimodal degree distribution can emerge in robust networks [41].
https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig4_HTML.jpg
Figure 4

Graph representations of receptor correlations. A, A graph representation of all significant correlations between receptors (after the Bonferroni correction; all Cook’s distances do not exceed 1.0). The inset shows the distribution of the vertex degrees. B, The neighborhood subgraph of the nociceptin receptor (OPRL1); marked in the center.

Next, the obtained correlation information was used to examine whether some receptors groups are more tightly interlinked than other receptors or, more presicely, whether the graph (Figure 4A) can be broken down into distinct receptor communities. Two community detection methods were used: the modularity algorithm and the clique percolation algorithm [42]. The modularity method revealed two major receptor communities (Figure 5). As recommended by Palla et al. [42], the clique percolation method was optimized using several correlation thresholds (T = 0.5, 0.6, 0.7, 0.8, and 0.9) and k-cliques of several sizes. The best separation was achieved with T = 0.6 and k = 4, which again revealed two distinct receptor communities (Figure 6). With the exception of one receptor (BDKRB2), the separation among the receptors was identical to the one obtained with the modularity method. Since the clique percolation method used more stringent criteria, it excluded some more weakly correlated receptors (importantly, they were not placed in the opposite community). These analyses suggest that the human brain has two functional receptor communities, within each of which the mRNA levels are strongly correlated and can potentially affect each other. The first community contains the glutamate receptor mGluR1, the dopamine receptor D2, the adrenergic receptor β3, the serotonin receptors 5-HT1B, 5-HT2C, 5-HT6, the cholinergic receptors M4 and M5, the bradykinin receptors B1 and B2, the cholecystokinin receptor CCK2, the CRH receptor CRF1, the galanin receptor Gal2, the NPY receptor Y6, the neurotensin receptor NT2, the oxytocin receptor, the somatostatin receptors SST3 and SST4, the tachykinin receptor NK2, the VIP receptor VPAC1, the purine receptor P2Y11, and the cannabinoid receptor CB2. The second community contains the glutamate receptors mGluR2, mGluR5, mGluR7, the dopamine receptor D1, the adrenergic receptors α1B, α1D, β1, the serotonin receptors 5-HT1A, 5-HT1F, 5-HT2A, 5-HT4, the cholinergic receptors M1 and M3, the histamine receptors H1 and H2, the MCH receptors MCH1 and MCH2, the NPY receptors Y1 and Y5, the nociceptin receptor (ORL-1), the somatostatin receptor SST1, and the VIP receptor VPAC2.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig5_HTML.jpg
Figure 5

The two communities of G protein-coupled neurotransmitter receptors detected with the modularity method.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-15-16/MediaObjects/12868_2013_Article_3465_Fig6_HTML.jpg
Figure 6

The two communities of G protein-coupled neurotransmitter receptors detected with the clique percolation method. The absolute values of correlations were thresholded at 0.6 (with the corresponding p < 10-15) and the clique number was set at k = 4.

Discussion

The Allen Human Brain Atlas is a relatively new database [39, 40] that continues to be updated and refined. In the absence of generally accepted standards for how gene expression data should be normalized and presented, the published expression values should be treated with caution. The expression of many receptors is highly consistent across individuals, but some receptors show a high degree of variability (Table 1). Among them is the dopamine receptor 4 (coded by the DRD4 gene), which has been extensively studied because of a functionally important polymorphism in its exon 3 [4347]. The origin of its inconsistent distribution across individuals is not clear and may be due to either unreliable detection or true expression differences in the population. Notably, no relationship has been established between the DRD4 alleles and their mRNA levels [48].

Caution should also be exercised in the interpretation of mRNA levels that show a consistent pattern across the subjects. For many receptors, the relationship between the mRNA and protein quantities is often poorly understood, and a change in one of these measures may not indicate a change in the other. A recent large-scale study has shown that, on average, mRNA levels explain around 40% of the variability in protein levels, and that the abundance of a protein is predominantly controlled by translation [49]. In addition, many neurotransmitter receptors operate in two different signaling modes: at the membrane surface through G-proteins and, when internalized, in an arrestin-dependent fashion [50]. Neurotransmitter receptor genes can produce several mRNA splice variants, some of which may be constitutively active (ligand-independent) [51], or have different internalization properties [52]. Also, protein molecules can be phosphorylated, glycosylated, and undergo other modifications [50, 5355]. These post-translational processes place severe limitations on functional inferences from mRNA data. On the other hand, mRNA quantification allows a high degree of specificity, which remains difficult to achieve in protein analyses. Post-translational modifications of protein molecules and the absence of specific antibodies for a number of neurotransmitter receptors (contrary to the claims of manufacturers) currently do not allow large scale quantifications of proteins in the entire brain. Even though the protein data remain limited, Table 1 provides information about the possible inter-individual variability of the mRNA levels of nearly all neurotransmitter receptors and will facilitate the interpretation of completed and future studies.

The analyzed mRNA levels in brain structures reflect the cumulative gene expression in several types of neuronal and glial cells, with a possible contribution from endothelial and ependymal cells. This lack of spatial precision makes the obtained results too “coarse” for the modeling of local neural circuits. However, an association between the abundance of two receptors over many brain regions is functionally meaningful, just as biologically meaningful information can be obtained from the correlation between the population numbers of two species across geographic areas (even if the species do not directly interact). Hypofunction or hyperfunction of a receptor in a class of cells is likely to affect the activity of their local neuroecosystems, which may induce changes in the expression of receptors in other cells [56]. Therefore, estimates of the most likely associations among receptors are important for the interpretation of receptor knockout models, as well as for the prediction of changes in other receptors associated with pharmacological targeting of a specific neurotransmitter receptor [57, 58]. At present, no comprehensive quantitative analysis exists to facilitate these theoretical considerations, and published data are likely to be biased by hypothesis-driven approaches, funding agency priorities, and attracting nodes in researcher networks. While the current analysis is a step forward, major theoretical breakthroughs can be expected when technical capabilities become sufficiently advanced to dynamically monitor entire receptor sets in single neurons and glial cells [35].

Currently little information is available about the correlation between the mRNA levels of receptors that form heteromeric complexes. Among them, the complex between the metabotropic glutamate receptor mGluR2 and the serotonin receptor 5-HT2A has been particularly well studied, partly because of its potential importance in schizophrenia and other related brain disorders [32, 59, 60]. It has been recently reported that the disruption of 5-HT2A receptor-dependent signaling can suppress mGluR2 transcription through epigenetic modifications in the mGluR2 gene promoter [61]. The present analysis found a highly significant positive correlation between the mRNA levels of these two receptors (0.49). However, mGluR2 had the highest positive correlations with the nociceptin receptor (ORL-1), the adrenergic α1D and β2 receptors, the histamine H2 receptor, and the purine P2Y6 receptor; and the 5-HT2A receptor had the highest positive correlations with the histamine H1 receptor (Figure 1), the serotonin 5-HT1F receptor, the muscarinic cholinergic M3 receptor, and the melanin-concentrating hormone receptors MCH1 and MCH2 (Table 2).

Two receptor communities were extracted from the data (Figures 5 and 6). There are many neural circuits where these receptors interact, but it remains unclear whether the entire communities can be assigned a biologically meaningful role. It should be noted that many of the receptors in the two “minimal” communities (Figure 6) control global brain functions, such as wakefulness and sleep [62]. The two communities can be differentially affected in some brain disorders. For example, the 5-HT1A, 5-HT2A and 5-HT4 receptors belong to the same community (Figure 6) and are expressed by neurons in the medial prefrontal cortex (mPFC) that project to the dorsal raphe nucleus and control serotonin release [63, 64]. Altered activity of these neurons has been implicated in mood disorders [63, 65, 66]. The exact structure of the communities is likely to become more refined as more data become available in the Allen Brain Atlas. In general, receptor network analyses hold great promise for understanding the brain in health and disease, as has been demonstrated by recent research [36, 6769].

The relatively simple distribution of correlations (Figure 3) raises interesting questions. Theoretically, such a distribution can be obtained from a single dynamical interaction. Depending on the numerical values of its coefficients, the same process can produce uncorrelated or highly correlated equilibrium values, even if the two receptors are strongly dynamically coupled [70]. Since theoretically all receptors can be expressed by all brain cells and they can only differ in their equilibrium levels (some mRNA amounts may be undetectably small), such qualitative uniformity remains an intriguing possibility.

Conclusions

Progress in neuroscience requires both accurate factual observations and complexity reduction. Since information processing in the brain depends on thousands of unique neurotransmitter-receptor interactions, understanding how these neurotransmitter-receptor pairs operate in functional groups is not only a theoretical imperative, but also a practical necessity. The obtained results suggest that the apparent complexity of neurotransmitter signaling has an underlying global structure, which is not readily detectable if receptor interactions are studied in isolation.

Methods

The human brain expression data of one hundred G protein-coupled neurotransmitter receptors (Table 1) were downloaded from the Allen Brain Atlas data portal (http://human.brain-map.org; the data release of March 7, 2013). Technical details about the brain donors, tissue preparation, specificity controls, and data normalization (including normalization across brains) are described in the Allen Human Brain Atlas Technical White Papers (Case Qualification and Donor Profiles, Microarray Survey, Microarray Data Normalization).

The normalized mRNA amounts in 169 brain regions were obtained from six available subjects (three Caucasian males (31, 55, and 57 years of age), two African-American males (24 and 39 years of age), and one Hispanic female (49 years of age)).

Of the analyzed regions, the 14 regions from the myelencephalon were the central glial substance, the arcuate nucleus of the medulla, the inferior olivary complex, the gracile nucleus, the cuneate nucleus, the raphe nuclei of the medulla, the central medullary reticular group, the lateral medullary reticular group, the gigantocellular group, the hypoglossal nucleus, the dorsal motor nucleus of the vagus, the spinal trigeminal nucleus, the vestibular nuclei, and the cochlear nuclei. The 12 regions from the pontine tegmentum were the pontine nuclei, the superior olivary complex, the central gray of the pons, the paramedian pontine reticular formation, the locus ceruleus, the nucleus subceruleus, the pontine raphe nucleus, the medial parabrachial nucleus, the lateral parabrachial nucleus, the facial motor nucleus, the abducens nucleus, and the trigeminal nuclei. The 27 regions from the cerebellum were 12 vermal areas (I-II, III, IV, V, VI, VIIAf, VIIAt, VIIB, VIIIA, VIIIB, IX, X), 11 lobules (III, IV, V, VI, Crus I, Crus II, VIIB, VIIIA, VIIIB, IX, X), and the four deep cerebellar nuclei (the fastigial nucleus, the globose nucleus, the emboliform nucleus, and the dentate nucleus). The 14 regions from the mesencephalon were the ventral tegmental area, the substantia nigra, the red nucleus, the central gray of the midbrain, the midbrain raphe nuclei, the midbrain reticular formation, the trochlear nucleus, the oculomotor nuclear complex, the Edinger-Westphal nucleus, the inferior colliculus, the superior colliculus, the pretectal region, the interstitial nucleus of Cajal, and the nucleus of Darkschewitsch. The 11 regions from the thalamic area were the subthalamus, the ventral thalamus, the posterior group of nuclei, the medial geniculate complex, the dorsal lateral geniculate nucleus, the dorsal division of the lateral group of nuclei, the ventral division of the lateral group of nuclei, the anterior group of nuclei, the medial group of nuclei, the caudal group of intralaminar nuclei, and the rostral group of intralaminar nuclei. The 19 regions from the epithalamus and the hypothalamus were the pineal, the habenular nuclei, the paraventricular thalamic nuclei, the posterior hypothalamic area, the lateral hypothalamic area, the mammillary region of the lateral hypothalamic area, the mammillary body, the supramammillary nucleus, the tuberomammillary nucleus, the tuberal region of the lateral hypothalamic area, the lateral tuberal nucleus, the perifornical nucleus, the ventromedial hypothalamic nucleus, the dorsomedial hypothalamic nucleus, the anterior hypothalamic area, the arcuate nucleus of the hypothalamus, the preoptic region, the paraventricular nucleus of the hypothalamus, and the supraoptic nucleus. The 9 regions from the striatum, pallidum, and septum were the head of the caudate nucleus, the body of the caudate nucleus, the tail of the caudate nucleus, the nucleus accumbens, the putamen, the external segment of the globus pallidus, the internal segment of the globus pallidus, the substantia innominata, and the septal nuclei. The 6 regions from the amygdala were the central nucleus, the basomedial nucleus, the cortico-medial area, the basolateral nucleus, the lateral nucleus, and the amygdaloid transition zone. Two other regions from the lateral pallium were the claustrum and the piriform cortex. The 7 regions from the hippocampal formation were the parahippocampal gyrus, the dentate gyrus, the CA1 field, the CA2 field, the CA3 field, the CA4 field, and the subiculum. The cingulate gyrus was subdivided into the frontal, parietal, and retrosplenial parts, and the insula was subdivided into the short and long gyri. The 9 regions from the temporal lobe were the temporal pole, planum polare, the transverse gyri, Heschl’s gyrus, the planum temporale, the superior temporal gyrus, the middle temporal gyrus, the inferior temporal gyrus, and the fusiform gyrus. The 6 regions from the occipital lobe were the occipital pole, the cuneus, the lingual gyrus, the superior occipital gyrus, the inferior occipital gyrus, and the occipito-temporal gyrus. The 6 regions from the parietal lobe were the precuneus, the posterior paracentral lobule, superior parietal lobule, the angular gyrus, the supramarginal gyrus, and the postcentral gyrus. The 19 regions from the frontal lobe were the paraterminal gyrus, the subcallosal gyrus, the parolfactory gyri, the anterior paracentral lobule, the precentral gyrus, the superior frontal gyrus, the middle frontal gyrus, the frontal operculum, the opercular part of the inferior frontal gyrus, the triangular part of the inferior frontal gyrus, the orbital part of the inferior frontal gyrus, the lateral orbital gyrus, the medial orbital gyrus, the posterior orbital gyrus, the anterior orbital gyrus, the gyrus rectus, the superior rostral gyrus, the inferior rostral gyrus, and the frontal pole. In addition, the expression data from the cingulum, the corpus callosum, and the choroid plexus of the lateral ventricle were used.

Expression data were available from four or more subjects in 86% of the 169 brain regions, and 53% of the 169 brain regions were represented by all six subjects. Only four brain regions (2%) were represented by a single subject. The median number of mRNA probes per gene was 3. One gene was analyzed with only one probe (ADORA2B) and one gene was analyzed with 89 probes (CNR1). Probes were located on different exons as much as possible when multiple probes were used for a gene (Allen Human Brain Atlas Technical White Paper: Microarray Survey).

The data were analyzed in Mathematica 9 (Wolfram Research, Inc.). The mean expression values of each brain region of each subject were obtained by averaging all probes, and the inter-subject variability was assessed by calculating the cross-correlations between all subject pairs (15 correlations; the median values are given in Table 1). Next, the overall mean values of each brain region were obtained by averaging all available subjects, and the correlations between all unique receptor pairs (4950) were calculated. In all correlation calculations, all 169 brain regions were used as the data points. For this sample size, a correlation of ±0.16 is significant with p < 0.05 and a correlation of ±0.34 is significant with p < 0.05/4950 (i.e., it is significant after the Bonferroni correction for the multiple tests).

In graph analyses, two receptors were considered to be connected by an edge only if their correlation was significant after the Bonferroni correction (i.e., if p < 0.05/4950) and, additionally, if all Cook’s distances in the linear regression model did not exceed 1.0 (to avoid the effect of influential outliers).

Functional receptor communities were analyzed using the modularity algorithm implemented in Mathematica 9 and the clique percolation method implemented in CFinder (http://www.cfinder.org) and based on a published algorithm [42].

The Mathematica notebooks are available in Additional file 1 and Additional file 2.

Declarations

Acknowledgements

This work was supported by UCSB Academic Senate Research Grants and the UCSB Open Access Fund Pilot Program.

Authors’ Affiliations

(1)
Department of Psychological and Brain Sciences, University of California

References

  1. Henny P, Brown MT, Micklem BR, Magill PJ, Bolam JP: Stereological and ultrastructural quantification of the afferent synaptome of individual neurons. Brain Struct Funct. 2013,  -in pressGoogle Scholar
  2. Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, Porkka-Heiskanen T: Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J Sleep Res. 2003, 12: 283-290. 10.1046/j.0962-1105.2003.00367.x.View ArticlePubMedGoogle Scholar
  3. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA. 2001, 98: 9407-9412. 10.1073/pnas.161292398.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El YM, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997, 388: 674-678. 10.1038/41771.View ArticlePubMedGoogle Scholar
  5. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK: Targeted disruption of the β2 adrenergic receptor gene. J Biol Chem. 1999, 274: 16694-16700. 10.1074/jbc.274.24.16694.View ArticlePubMedGoogle Scholar
  6. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH: Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA. 1998, 95: 15049-15054. 10.1073/pnas.95.25.15049.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Weisstaub NV, Zhou M, Lira A, Lambe E, Gonzalez-Maeso J, Hornung JP, Sibille E, Underwood M, Itohara S, Dauer WT, Ansorge MS, Morelli E, Mann JJ, Toth M, Aghajanian G, Sealfon SC, Hen R, Gingrich JA: Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science. 2006, 313: 536-540. 10.1126/science.1123432.View ArticlePubMedGoogle Scholar
  8. Compan V, Zhou M, Grailhe R, Gazzara RA, Martin R, Gingrich J, Dumuis A, Brunner D, Bockaert J, Hen R: Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice. J Neurosci. 2004, 24: 412-419. 10.1523/JNEUROSCI.2806-03.2004.View ArticlePubMedGoogle Scholar
  9. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, Katsuura G, Shigemoto R, Ohishi H, Nomura S, Nakamura K, Nakao K, Katsuki M, Nakanishi S: Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science. 1996, 273: 645-647. 10.1126/science.273.5275.645.View ArticlePubMedGoogle Scholar
  10. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S: Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997, 19: 837-848. 10.1016/S0896-6273(00)80965-4.View ArticlePubMedGoogle Scholar
  11. Segu L, Lecomte MJ, Wolff M, Santamaria J, Hen R, Dumuis A, Berrard S, Bockaert J, Buhot MC, Compan V: Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice. PLoS One. 2010, 5: e9529-10.1371/journal.pone.0009529.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev. 1992, 72: 165-229.PubMedGoogle Scholar
  13. Duvernoy HM, Delon S, Vannson JL: Cortical blood vessels of the human brain. Brain Res Bull. 1981, 7: 519-579. 10.1016/0361-9230(81)90007-1.View ArticlePubMedGoogle Scholar
  14. Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, Janigro D: Regional variation in brain capillary density and vascular response to ischemia. Brain Res. 2001, 910: 81-93. 10.1016/S0006-8993(01)02637-3.View ArticlePubMedGoogle Scholar
  15. Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B, Silver J, Weeber EJ, Sweatt JD, Deneris ES: Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron. 2003, 37: 233-247. 10.1016/S0896-6273(02)01167-4.View ArticlePubMedGoogle Scholar
  16. Gutknecht L, Araragi N, Merker S, Waider J, Sommerlandt FM, Mlinar B, Baccini G, Mayer U, Proft F, Hamon M, Schmitt AG, Corradetti R, Lanfumey L, Lesch KP: Impacts of brain serotonin deficiency following Tph2 inactivation on development and raphe neuron serotonergic specification. PLoS One. 2012, 7: e43157-10.1371/journal.pone.0043157.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Migliarini S, Pacini G, Pelosi B, Lunardi G, Pasqualetti M: Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation. Mol Psychiatry. 2013, 18: 1106-1118. 10.1038/mp.2012.128.View ArticlePubMedGoogle Scholar
  18. Vitalis T, Cases O, Passemard S, Callebert J, Parnavelas JG: Embryonic depletion of serotonin affects cortical development. Eur J Neurosci. 2007, 26: 331-344. 10.1111/j.1460-9568.2007.05661.x.View ArticlePubMedGoogle Scholar
  19. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR: Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004, 56: 532-539. 10.1002/ana.20226.View ArticlePubMedGoogle Scholar
  20. Bruno JP, Snyder AM, Stricker EM: Effect of dopamine-depleting brain lesions on suckling and weaning in rats. Behav Neurosci. 1984, 98: 156-161.View ArticlePubMedGoogle Scholar
  21. Castaneda E, Whishaw IQ, Lermer L, Robinson TE: Dopamine depletion in neonatal rats: effects on behavior and striatal dopamine release assessed by intracerebral microdialysis during adulthood. Brain Res. 1990, 508: 30-39. 10.1016/0006-8993(90)91113-U.View ArticlePubMedGoogle Scholar
  22. Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA, Biaggioni I: Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991, 18: 1-8. 10.1161/01.HYP.18.1.1.View ArticlePubMedGoogle Scholar
  23. Timmers HJ, Deinum J, Wevers RA, Lenders JW: Congenital dopamine-beta-hydroxylase deficiency in humans. Ann N Y Acad Sci. 2004, 1018: 520-523. 10.1196/annals.1296.064.View ArticlePubMedGoogle Scholar
  24. Arcelli P, Frassoni C, Regondi MC, De BS, Spreafico R: GABAergic neurons in mammalian thalamus: a marker of thalamic complexity?. Brain Res Bull. 1997, 42: 27-37. 10.1016/S0361-9230(96)00107-4.View ArticlePubMedGoogle Scholar
  25. Sherman SM, Guillery RW: Exploring the Thalamus and Its Role in Cortical Function. 2006, Cambridge: The MIT PressGoogle Scholar
  26. Yamazoe I, Takeuchi Y, Matsushita H, Kawano H, Sawada T: Serotonergic heterotypic sprouting in the unilaterally dopamine-depleted mouse neostriatum. Dev Neurosci. 2001, 23: 78-83. 10.1159/000048698.View ArticlePubMedGoogle Scholar
  27. Martin P, Ohno M, Southerland SB, Mailman RB, Suzuki K: Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse. Brain Res Dev Brain Res. 1994, 77: 215-225. 10.1016/0165-3806(94)90198-8.View ArticlePubMedGoogle Scholar
  28. Thomas SA, Matsumoto AM, Palmiter RD: Noradrenaline is essential for mouse fetal development. Nature. 1995, 374: 643-646. 10.1038/374643a0.View ArticlePubMedGoogle Scholar
  29. Dulcis D, Jamshidi P, Leutgeb S, Spitzer NC: Neurotransmitter switching in the adult brain regulates behavior. Science. 2013, 340: 449-453. 10.1126/science.1234152.View ArticlePubMedGoogle Scholar
  30. Albizu L, Moreno JL, Gonzalez-Maeso J, Sealfon SC: Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets. 2010, 9: 636-650. 10.2174/187152710793361586.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, Battini L, Gusella GL, Lachmann A, Ma’ayan A, Blitzer RD, Devi LA: Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One. 2012, 7: e29239-10.1371/journal.pone.0029239.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Fribourg M, et al: Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell. 2011, 147: 1011-1023. 10.1016/j.cell.2011.09.055.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Albizu L, Holloway T, Gonzalez-Maeso J, Sealfon SC: Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology. 2011, 61: 770-777. 10.1016/j.neuropharm.2011.05.023.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Lohse MJ: Dimerization in GPCR mobility and signaling. Curr Opin Pharmacol. 2010, 10: 53-58. 10.1016/j.coph.2009.10.007.View ArticlePubMedGoogle Scholar
  35. Janušonis S: Relationships among variables and their equilibrium values: caveats of time-less interpretation. Biol Rev Camb Philos Soc. 2012, 87: 275-289. 10.1111/j.1469-185X.2011.00194.x.View ArticlePubMedGoogle Scholar
  36. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF: Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry. 2008, 13: 786-799. 10.1038/mp.2008.38. 741View ArticlePubMedGoogle Scholar
  37. Templin JS, Bang SJ, Soiza-Reilly M, Berde CB, Commons KG: Patterned expression of ion channel genes in mouse dorsal raphe nucleus determined with the Allen Mouse Brain Atlas. Brain Res. 2012, 1457: 1-12.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Ayoub AE, Oh S, Xie Y, Leng J, Cotney J, Dominguez MH, Noonan JP, Rakic P: Transcriptional programs in transient embryonic zones of the cerebral cortex defined by high-resolution mRNA sequencing. Proc Natl Acad Sci USA. 2011, 108: 14950-14955. 10.1073/pnas.1112213108.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Ball S, Gilbert TL, Overly CC: The human brain online: an open resource for advancing brain research. PLoS Biol. 2012, 10: e1001453-10.1371/journal.pbio.1001453.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Shen EH, Overly CC, Jones AR: The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain. Trends Neurosci. 2012, 35: 711-714. 10.1016/j.tins.2012.09.005.View ArticlePubMedGoogle Scholar
  41. Sonawane AR, Bhattacharyay A, Santhanam MS, Ambika G: Evolving networks with bimodal degree distribution. Eur Physical J B. 2012, 85: 118.View ArticleGoogle Scholar
  42. Palla G, Derenyi I, Farkas I, Vicsek T: Uncovering the overlapping community structure of complex networks in nature and society. Nature. 2005, 435: 814-818. 10.1038/nature03607.View ArticlePubMedGoogle Scholar
  43. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ: A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet. 1993, 2: 767-773. 10.1093/hmg/2.6.767.View ArticlePubMedGoogle Scholar
  44. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH: Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet. 1996, 12: 78-80. 10.1038/ng0196-78.View ArticlePubMedGoogle Scholar
  45. Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, Ryder OA, Spence MA, Swanson JM, Moyzis RK: The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet. 2004, 74: 931-944. 10.1086/420854.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Sasaki JY, Kim HS, Mojaverian T, Kelley LD, Park IY, Janušonis S: Religion priming differentially increases prosocial behavior among variants of the dopamine D4 receptor (DRD4) gene. Soc Cogn Affect Neurosci. 2013, 8: 209-215. 10.1093/scan/nsr089.PubMed CentralView ArticlePubMedGoogle Scholar
  47. Ding YC, Chi HC, Grady DL, Morishima A, Kidd JR, Kidd KK, Flodman P, Spence MA, Schuck S, Swanson JM, Zhang YP, Moyzis RK: Evidence of positive selection acting at the human dopamine receptor D4 gene locus. Proc Natl Acad Sci USA. 2002, 99: 309-314. 10.1073/pnas.012464099.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Simpson J, Vetuz G, Wilson M, Brookes KJ, Kent L: The DRD4 receptor Exon 3 VNTR and 5′ SNP variants and mRNA expression in human post-mortem brain tissue. Am J Med Genet B Neuropsychiatr Genet. 2010, 153B: 1228-1233.PubMedGoogle Scholar
  49. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M: Global quantification of mammalian gene expression control. Nature. 2011, 473: 337-342. 10.1038/nature10098.View ArticlePubMedGoogle Scholar
  50. Luttrell LM, Gesty-Palmer D: Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev. 2010, 62: 305-330. 10.1124/pr.109.002436.PubMed CentralView ArticlePubMedGoogle Scholar
  51. Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A: Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol. 1999, 55: 910-920.PubMedGoogle Scholar
  52. Mnie-Filali O, Amraei MG, Benmbarek S, Archer-Lahlou E, Penas-Cazorla R, Vilaro MT, Boye SM, Pineyro G: Serotonin 4 receptor (5-HT4R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B. Cell Signal. 2010, 22: 501-509. 10.1016/j.cellsig.2009.11.004.View ArticlePubMedGoogle Scholar
  53. Salom D, Wang B, Dong Z, Sun W, Padayatti P, Jordan S, Salon JA, Palczewski K: Post-translational modifications of the serotonin type 4 receptor heterologously expressed in mouse rod cells. Biochemistry. 2012, 51: 214-224. 10.1021/bi201707v.PubMed CentralView ArticlePubMedGoogle Scholar
  54. Sen N, Snyder SH: Protein modifications involved in neurotransmitter and gasotransmitter signaling. Trends Neurosci. 2010, 33: 493-502. 10.1016/j.tins.2010.07.004.PubMed CentralView ArticlePubMedGoogle Scholar
  55. Kursawe R, Paschke R: Modulation of TSHR signaling by posttranslational modifications. Trends Endocrinol Metab. 2007, 18: 199-207. 10.1016/j.tem.2007.05.002.View ArticlePubMedGoogle Scholar
  56. Delille HK, Mezler M, Marek GJ: The two faces of the pharmacological interaction of mGlu2 and 5-HT2A - Relevance of receptor heterocomplexes and interaction through functional brain pathways. Neuropharmacology. 2013, 70: 296-305.View ArticlePubMedGoogle Scholar
  57. Rozenfeld R, Devi LA: Receptor heteromerization and drug discovery. Trends Pharmacol Sci. 2010, 31: 124-130. 10.1016/j.tips.2009.11.008.PubMed CentralView ArticlePubMedGoogle Scholar
  58. Rozenfeld R, Devi LA: Exploring a role for heteromerization in GPCR signalling specificity. Biochem J. 2011, 433: 11-18. 10.1042/BJ20100458.View ArticlePubMedGoogle Scholar
  59. Gonzalez-Maeso J, Sealfon SC: Psychedelics and schizophrenia. Trends Neurosci. 2009, 32: 225-232. 10.1016/j.tins.2008.12.005.View ArticlePubMedGoogle Scholar
  60. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008, 452: 93-97. 10.1038/nature06612.PubMed CentralView ArticlePubMedGoogle Scholar
  61. Kurita M, Moreno JL, Holloway T, Kozlenkov A, Mocci G, Garcia-Bea A, Hanks JB, Neve R, Nestler EJ, Russo SJ, Gonzalez-Maeso J: Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol Pharmacol. 2013, 83: 1166-1175. 10.1124/mol.112.084582.PubMed CentralView ArticlePubMedGoogle Scholar
  62. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW: Control of sleep and wakefulness. Physiol Rev. 2012, 92: 1087-1187. 10.1152/physrev.00032.2011.PubMed CentralView ArticlePubMedGoogle Scholar
  63. Celada P, Puig MV, Martin-Ruiz R, Casanovas JM, Artigas F: Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotox Res. 2002, 4: 409-419. 10.1080/10298420290030550.View ArticlePubMedGoogle Scholar
  64. Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J, Barrot M, Debonnel G: Frontocortical 5-HT(4) receptors exert positive feedback on serotonergic activity: Viral transfections, subacute and chronic treatments with 5-HT(4) agonists. Biol Psychiatry. 2005, 57: 918-925. 10.1016/j.biopsych.2004.12.023.View ArticlePubMedGoogle Scholar
  65. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, Lambas-Senas L, Wiborg O, Haddjeri N, Pineyro G, Sadikot AF, Debonnel G: Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007, 55: 712-725. 10.1016/j.neuron.2007.07.041.View ArticlePubMedGoogle Scholar
  66. Vollenweider FX, Kometer M: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010, 11: 642-651. 10.1038/nrn2884.View ArticlePubMedGoogle Scholar
  67. Hu VW, Addington A, Hyman A: Novel autism subtype-dependent genetic variants are revealed by quantitative trait and subphenotype association analyses of published GWAS data. PLoS One. 2011, 6: e19067-10.1371/journal.pone.0019067.PubMed CentralView ArticlePubMedGoogle Scholar
  68. Lee TL, Raygada MJ, Rennert OM: Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. Gene. 2012, 496: 88-96. 10.1016/j.gene.2012.01.020.PubMed CentralView ArticlePubMedGoogle Scholar
  69. Lang UE, Borgwardt S: Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013, 31: 761-777. 10.1159/000350094.View ArticlePubMedGoogle Scholar
  70. Janušonis S: Direct interaction with no correlation: an experimental pitfall in neural systems. J Neurosci Methods. 2012, 206: 151-157. 10.1016/j.jneumeth.2012.02.012.View ArticlePubMedGoogle Scholar

Copyright

© Janušonis; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement